Knopp Neurosciences is a drug discovery and development company focused
on delivering breakthrough treatments in neurological disorders through
innovation, experience and partnership. Knopp’s lead compound,
KNS-760704, is currently in clinical development for amyotrophic lateral
sclerosis (ALS), often referred to as “Lou Gehrig’s disease,” with
additional indications under investigation.
Knopp employs innovative approaches to persistent
problems in drug discovery and development. Knopp has aligned with world
leaders in the fields supporting drug discovery and development. Knopp
leverages their talents to accelerate and advance the diagnosis and
treatment of neurological disorders, including ALS.
